[Hyperprolactinemia associated with neuroleptic treatment: clinical characteristics and an impact on sexual function].

Aim: To study clinical characteristics of antipsychotic-induced hyperprolactinemia (AIH) and an impact of AIH on sexual function in patients with mental disorders treated with neuroleptics for a long time.

Material And Methods: A cross-sectional study of 244 consecutive psychiatric in-patients (F/M=140/104) with mental disorders currently taking antipsychotics was carried out. The patients were screened for serum prolactin, sex hormones and gonadotropin levels.

Change in platelet monoamine oxidase activity in the acutest period of ischemic stroke is associated with the degree of neurological recovery.

We studied monoamine oxidase activity (MAO) in platelets of patients in the acute period of ischemic stroke. Neurological deficit was evaluated by the data of clinical examinations and scales. In 80% patients MAO activity was considerably increased on 3-5 day after stroke.

Contribution of leptin to the formation of neuroleptic obesity in patients with schizophrenia during antipsychotic therapy.

We studied the dynamics of serum leptin level and some anthropometric values in patients with schizophrenia treated with risperidone, olanzapine, and clozapine showed gender-dependent specific correlations between the studied parameters.

Effect of prenatal lead exposure on superoxide dismutase activity in the brain and liver of rat fetuses.

Prenatal lead exposure had a damaging effect on Cu/Zn superoxide dismutase activity in the brain and liver of rat fetuses (20 days of gestation). The decrease in Cu/Zn superoxide dismutase activity in the brain and liver of treated fetuses reflects activation of free radical processes and impairment of the antioxidant defense system during prenatal lead exposure.

Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.

Plasma prolactin concentration was measured in patients with schizophrenia and schizoaffective disorders receiving therapy with risperidone, olanzapine, and quetiapine and compared with the corresponding parameter in patient receiving typical neuroleptic drug haloperidol. We evaluated the specific effects of the test drugs on prolactin concentration in men and women.

Clinical evaluation of non-narcotic substitutive effects produced by ANAR during the therapy of patients with heroin abuse.

The substitutive effects of potentiated ANAR (affinely purified antibodies to morphine hydrochloride in dilutions C30 and C200) used to relieve the opium withdrawal syndrome in 149 patients with heroin abuse were studied in an open standardized clinical trial. Over the first 2 days of therapy the preparation produced the vegetostabilizing, sedative, anxiolytic, neuroprotective, and moderate analgetic effects. During the therapy of patients with opium intoxication ANAR delayed the appearance of symptoms for the opium withdrawal syndrome by 18-30 h.

Use of ANAR for the therapy of opium withdrawal syndrome.

We studied the efficiency of ANAR containing antibodies to morphine (dilutions C300 and C200) in the therapy of patients with the opium withdrawal syndrome. In patients with moderate to severe forms of the opium withdrawal syndrome therapeutic activity of ANAR was comparable to that of standard symptomatic drugs. ANAR possessed vegetostabilizing, sedative, and analgetic properties.

Psychotropic activity of the antialcohol preparation Proproten-100.

Antidepressant activity of Proproten-100 (antibodies to brain-specific S100 protein in ultralow doses) in patients with stage II alcohol dependence and alcohol withdrawal syndrome was studied in an open comparative clinical trial. The tricyclic antidepressant amitriptyline and benzodiazepine tranquilizer phenazepam served as reference preparations. Anxiolytic activity of Proproten-100 was highly competitive with that of phenazepam.

Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome.

The efficiency of Proproten-100 containing antibodies to S100 protein in ultralow doses and used to relieve somatovegetative and psychoneurological manifestations of the alcohol withdrawal syndrome was studied in a double-blind, placebo-controlled clinical trial. The preparation possessed anxiolytic, sedative, hypnagogic, and vegetostabilizing properties. Proproten-100 more rapidly relieved the alcohol withdrawal syndrome than standard drugs (by 2 times).

Use of potentiated preparations to relieve alcohol and opium withdrawal syndromes.

The efficiency of potentiated preparations from ethanol and morphine hydrochloride in the therapy of patients with alcohol and opium withdrawal syndromes was compared in an open clinical trial. Potentiated ethanol relieved the major clinical manifestations, possessed hypnagogic properties, and reduced the severity of neurological and vegetative disorders in patients with the alcohol withdrawal syndrome. Potentiated morphine produced the anxiolytic, myorelaxing, and analgetic effects.